4BIO Capital, a London, UK-based international venture capital firm investing in advanced therapies and other emerging technologies, entered into an investment agreement with the Development Bank of Japan Inc., Japan’s sovereign development bank, for its third fund, 4BIO Ventures III.
The Group is targeting $200-300m for the final close of the fund, expected to be reached in 2024.
4BIO Ventures III is already deploying capital and is focused on forming and investing in private companies addressing the world’s most impactful disease areas by developing advanced therapies and other emerging technologies, including cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. The objective is to create and invest in, support, and grow early-stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. 4BIO continues to prioritise novel technologies that resolve the largest industry pain points of advanced therapies in order to enable next-generation therapeutic assets.
By connecting Japan’s startup ecosystem with its counterparts overseas, DBJ and its subsidiary, DBJ Capital K.K., will work alongside 4BIO Capital to support the creation of new, potentially life-transforming medical treatments for all patients around the world.
Led by Dmitry Kuzmin, Managing Partner, 4BIO Capital has a team that comprises advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine.